Dr. Reddy's Laboratories Q1 FY27: net profit down 69% to ₹444 crore, revenue down 6%
Dr. Reddy's Laboratories (BSE: DRREDDY) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹8,100 crore (−5.5% year on year), net profit of ₹444 crore (−68.7%), earnings per share of ₹5.33. The company is valued at about ₹1.03…
What happened
Dr. Reddy's Laboratories (BSE: DRREDDY) informed the stock exchanges on 23 October 2026 at 05:30 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹8,100 crore (−5.5% year on year), net profit of ₹444 crore (−68.7%), earnings per share of ₹5.33.
From the filing: "Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b."
Company snapshot
Dr. Reddy's Laboratories is a large-cap company in the Healthcare sector, with a market value of about ₹1.03 lakh crore.
The stock last traded at ₹1,229.5, against a 52-week range of ₹1,101–₹1,414.9 (13.1% below the high).
Before this filing the shares had moved +3.9% over the month and +6.7% over three months. Average daily turnover over the last 20 sessions was about ₹244 crore.
Promoters held 26.64% at the end of Q1 FY27, up 0.01% points from the previous quarter. Foreign institutions owned 32.07% and domestic institutions 31.74%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 8,572 | 1,418.1 | 17.04 |
| Q2 FY26 | 8,828 | 1,347.1 | 16.18 |
| Q3 FY26 | 8,753 | 1,209.9 | 14.53 |
| Q4 FY26 | 7,546 | 220.9 | 2.65 |
| Q1 FY27 | 8,100 | 444.3 | 5.33 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.9% over five days; 54% of them rose the next day.
Market-wide, 9,702 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 23 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.